Article
05 Dec 2025
United States Patent And Trademark Office Issues Revised Guidance On Inventorship For AI-Assisted Inventions
AUTHORS CONTENT
Article
13 Oct 2025
USPTO Encourages AI Innovation As Federal Circuit Exercises Caution
Article
10 Oct 2025
Protecting AI With IP: Comparing Approaches Taken In The US And UK
Article
22 Sep 2025
IP Transactions: A Litigator's Perspective
Article
26 May 2025
Generative AI And Copyright Law, Part Two: Fair Use And Infringement Risks (Podcast)
Article
19 May 2025
United States Copyright Office Weighs In On Fair Use Defense For Generative AI Training
Article
28 Apr 2025
Developing An IP Strategy For Protecting AI Assets And Outputs In An Evolving World
Article
24 Mar 2025
Appellate Court Confirms Copyright Statute Limits Authorship To Humans, Foreclosing Copyright Registration For Content Solely Generated By AI
Article
17 Feb 2025
ROSS AI Decision Gives Early Indication Of Strengths And Weaknesses Of Fair Use Defense
Article
13 Feb 2025
Human Input Necessary For Copyrightability Of Works Created With Artificial Intelligence
Article
05 Feb 2025
Concerns Related To DeepSeek's Training Techniques May Focus On IP Issues
Article
23 Jul 2024
USPTO Provides Insight Into Patent Eligibility In The Context Of AI
Article
23 Feb 2024
USPTO: AI Use In Invention Process Does Not Foreclose Patentability
Article
15 Feb 2024
Corporate Governance Spotlight: Considerations For Protecting Valuable AI-Related Assets
Article
12 Jan 2024
Can AI Be An Inventor? The US, UK, EPO And German Approach
Article
29 Nov 2022
7 Key Takeaways For Litigating Willful Patent Infringement
Article
08 Apr 2022
Antibody Combinations In Immunotherapy Offer New Opportunities For Innovators To Strengthen IP Protections
Article
24 Mar 2022
Talk In The Biotech Industry Has Focused On The Broad Institute's Big Win—But Will Continued Scientific Development Minimize Its Impact?
Article
15 Apr 2021
Patent Considerations For Optimizing Immunotherapies With The Help Of Artificial Intelligence
Article
12 Jan 2021
Orange Book Transparency Act: New Obligations For Drug Patent Listings
